JULY 2018 – Our own Dr. Jaskula-Sztul was awarded the North American Neuroendocrine Tumor Society (NANETS) Basic/Translational Science Investigator (BTSI) Award, which is funded by the Neuroendocrine Tumor Research Foundation (NETRF).
Dr. Jaskula-Sztul’s study, Novel antibody-drug conjugate (ADC) for pancreatic neuroendocrine tumor (PanNET) Targeted Therapy, will explore a novel delivery system for therapy, using an approach designed to increase precision and efficacy while reducing risks.
Read more at: https://netrf.org/2018/07/10/new-grant-explores-novel-drug-delivery-system/
